AUGMENTIN INTRAVENOUS 1.2 gvial

País: Singapur

Idioma: anglès

Font: HSA (Health Sciences Authority)

ingredients actius:

Amoxycillin Sodium 1060.18 mg eqv. to Amoxicillin free acid; Potassium Clavulanate 238.25 mg eqv. to Clavulanic acid

Disponible des:

GLAXOSMITHKLINE PTE LTD

Codi ATC:

J01CR02

Dosis:

1 g/vial

formulario farmacéutico:

INJECTION, POWDER, FOR SOLUTION

Composición:

Amoxycillin Sodium 1060.18 mg eqv. to Amoxicillin free acid 1000 mg/vial; Potassium Clavulanate 238.25 mg eqv. to Clavulanic acid 200 mg/vial

Vía de administración:

INTRAVENOUS

tipo de receta:

Prescription Only

Fabricat per:

SmithKline Beecham Limited

Estat d'Autorització:

ACTIVE

Data d'autorització:

1988-06-08

Informació per a l'usuari

1
AUGMENTIN INTRAVENOUS
AMOXICILLIN SODIUM - POTASSIUM CLAVULANATE
QUALITATIVE AND QUANTITATIVE COMPOSITION
_AUGMENTIN_
600 mg intravenous: 500 mg amoxicillin (as amoxicillin sodium) and
100 mg clavulanic acid (as potassium clavulanate) for reconstitution
as an intravenous
injection or infusion.
_AUGMENTIN_
1.2 g intravenous: 1 g amoxicillin (as amoxicillin sodium) and 200 mg
clavulanic acid (as potassium clavulanate)
_ _
for reconstitution as an intravenous
injection or infusion.
PHARMACEUTICAL FORM
Sterile powder for injection.
CLINICAL PARTICULARS
INDICATIONS
AUGMENTIN should be used in accordance with local official
antibiotic-prescribing
guidelines and local susceptibility data.
_AUGMENTIN_
is indicated for short-term treatment of bacterial infections at the
following
sites:
_Upper respiratory tract infections (including ENT) _
e.g. recurrent tonsillitis, sinusitis,
otitis media.
_Lower respiratory tract infections _
e.g. acute exacerbation of chronic bronchitis, lobar and
bronchopneumonia.
_Genito-urinary tract infections _
e.g. cystitis, urethritis, pyelonephritis.
_Skin and soft tissue infections,_
e.g. boils, abscesses, cellulitis, wound infections.
_ _
_Bone and joint infections _
e.g. osteomyelitis.
_Other infections _
e.g. intra-abdominal sepsis.
_ _
_AUGMENTIN_
intravenous is also indicated for prophylaxis against infection which
may
be associated with major surgical procedures such as gastrointestinal,
pelvic, head and
neck, cardiac, renal, joint replacement and biliary tract.
Susceptibility to AUGMENTIN will vary with geography and time (see
Pharmacological
Properties, Pharmacodynamics for further information). Local
susceptibility data should
be consulted where available, and microbiological sampling and
susceptibility testing
performed where necessary.
Infections caused by amoxicillin-susceptible organisms are amenable to
_AUGMENTIN_
treatment due to its amoxicillin content. Mixed infections caused by
amoxicillin -
2
susceptible organisms in conjunction with
_AUGMENTIN_
-susceptible
β
-lactamase

Fitxa tècnica

1
AUGMENTIN INTRAVENOUS
AMOXICILLIN SODIUM - POTASSIUM CLAVULANATE
QUALITATIVE AND QUANTITATIVE COMPOSITION
_AUGMENTIN_
600 mg intravenous: 500 mg amoxicillin (as amoxicillin sodium) and
100 mg clavulanic acid (as potassium clavulanate) for reconstitution
as an intravenous
injection or infusion.
_AUGMENTIN_
1.2 g intravenous: 1 g amoxicillin (as amoxicillin sodium) and 200 mg
clavulanic acid (as potassium clavulanate)
_ _
for reconstitution as an intravenous
injection or infusion.
PHARMACEUTICAL FORM
Sterile powder for injection.
CLINICAL PARTICULARS
INDICATIONS
AUGMENTIN should be used in accordance with local official
antibiotic-prescribing
guidelines and local susceptibility data.
_AUGMENTIN_
is indicated for short-term treatment of bacterial infections at the
following
sites:
_Upper respiratory tract infections (including ENT) _
e.g. recurrent tonsillitis, sinusitis,
otitis media.
_Lower respiratory tract infections _
e.g. acute exacerbation of chronic bronchitis, lobar and
bronchopneumonia.
_Genito-urinary tract infections _
e.g. cystitis, urethritis, pyelonephritis.
_Skin and soft tissue infections,_
e.g. boils, abscesses, cellulitis, wound infections.
_ _
_Bone and joint infections _
e.g. osteomyelitis.
_Other infections _
e.g. intra-abdominal sepsis.
_ _
_AUGMENTIN_
intravenous is also indicated for prophylaxis against infection which
may
be associated with major surgical procedures such as gastrointestinal,
pelvic, head and
neck, cardiac, renal, joint replacement and biliary tract.
Susceptibility to AUGMENTIN will vary with geography and time (see
Pharmacological
Properties, Pharmacodynamics for further information). Local
susceptibility data should
be consulted where available, and microbiological sampling and
susceptibility testing
performed where necessary.
Infections caused by amoxicillin-susceptible organisms are amenable to
_AUGMENTIN_
treatment due to its amoxicillin content. Mixed infections caused by
amoxicillin -
2
susceptible organisms in conjunction with
_AUGMENTIN_
-susceptible
β
-lactamase